Rheumatoid Arthritis

The findings provide an alternative delivery strategy for peptide-based drugs and suggest that such techniques and principles could be applied to a broader range of drugs.

Adalimumab-aacf (Idacio) is indicated for chronic conditions such as rheumatoid arthritis, plaque psoriasis, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and juvenile idiopathic arthritis.

Otilimab also inhibits the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

Researchers expect to file for FDA approval within the year following the successful phase 3 trial.

Treatment with biologic disease-modifying antirheumatic drugs associated with a higher overall risk, incidence, and recurrence of herpes zoster for patients with rheumatoid arthritis.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Some anti-abortion laws may lead to legal action against health care providers who prescribe or provide medications that can be used to induce abortions.

Tocilizumab (Actemra) is indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.

Utilization of the RAPID3 tool can be a beneficial way for pharmacists to complete disease activity assessments without physically seeing the patient in a clinic setting.

Baricitinib (Olumiant) is indicated for the treatment of rheumatoid arthritis and COVID-19 in hospitalized adults.

In addition to the new approval for rheumatoid arthritis, Riabni has already been approved for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.

Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Patients with rheumatoid arthritis taking at least 3 targeted therapies were found to have a greater risk of developing herpes zoster.

Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.

Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.

Olumiant shows favorable long-term safety profile in rheumatoid arthritis.

Study evaluates the safety profile of upadacitinib at 15 mg and 30 mg once daily for patients with moderately to severely active rheumatoid arthritis.

Agency gives green light to supplemental new drug application for repository corticotropin injection.

Xeljanz can be used for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.

AbbVie announced positive top-line results from a phase 3 trial for the efficacy and safety of upadacitinib for individuals with the rheumatic disease.

Oral use of glucosamine hydrochloride may reduce pain related to rheumatoid arthritis.

Ten quiz questions to assess your knowledge on common rheumatoid arthritis treatments.

A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.

After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.

The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.